Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine during phaeochromocytoma surgery

被引:16
|
作者
Colson, P
Ryckwaert, F
Ribstein, J
Mann, C
Dareau, S
机构
[1] Hop Arnaud de Villeneuve, Serv Anesthesie Reanimat B, F-34295 Montpellier, France
[2] Hop Arnaud de Villeneuve, Serv Med Interne G, F-34295 Montpellier, France
关键词
surgery; pheochromocytoma; blood pressure; calcium antagonist;
D O I
10.1111/j.1399-6576.1998.tb05387.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Favourable outcome of phaeochromocytoma surgery requires that paroxysmal hypertension and arrhythmia be controlled, and that hypotension be prevented. Is nicardipine, a calcium channel blocking drug, always adequate ? Methods: Nineteen consecutive patients underwent surgery for phaeochromocytoma. Management was standardised with regards to anaesthesia and antihypertensive treatment. Nicardipine was used as a vasodilator and was given in order to maintain systemic vascular resistance lower than 1600 dyn.s.cm(-5). Results: Hypertension did not occur at any time during surgery in 6/19 patients. Blood pressure rose acutely in 3/19 patients at the time of tracheal intubation or surgical approach to the tumour, and was controlled by increased depth of anaesthesia. Hypertensive episodes occurred in 11/19 patients during tumour manipulation. Nicardipine always succeeded in maintaining low systemic vascular resistance but its dosage varied widely between patients (0.5 to 70 mg), a fact that may be accounted for by the striking intersubject variability of haemodynamic behaviour during surgery. In 7/11 patients, despite nicardipine treatment, sustained increase in blood pressure persisted with increased cardiac index, but low systemic vascular resistance. Following tumour removal, transient serious hypotension (MAP <60 mmHg) occurred in 4 patients, and was corrected by fluid volume expansion. Perioperative incidence of hypertension or hypotension was not related to preoperative clinical status. Conclusion: Adequate management of patients operated upon for phaeochromocytoma requires invasive monitoring, since the mechanisms underlying hypertensive crises are heterogeneous with regards to systemic vascular resistance and not predictable from preoperative data. Nicardipine provides a good control of vasoconstriction during phaeochromocytoma surgery with limited risk of serious hypotension after tumour removal.
引用
收藏
页码:1114 / 1119
页数:6
相关论文
共 50 条
  • [31] LONG-TERM EFFICACY OF NICARDIPINE, A NEW CALCIUM-CHANNEL BLOCKER, IN CHRONIC STABLE ANGINA
    DEEDWANIA, PC
    THAO, TP
    ANDREW, HT
    CLINICAL RESEARCH, 1985, 33 (01): : A20 - A20
  • [32] Treatment of Serious Calcium Channel Blocker Overdose With Levosimendan, a Calcium Sensitizer
    Varpula, Tero
    Rapola, Janne
    Sallisalmi, Marko
    Kurola, Jouni
    ANESTHESIA AND ANALGESIA, 2009, 108 (03): : 790 - 792
  • [34] THE EFFECT OF NICARDIPINE, A CALCIUM-CHANNEL BLOCKER, ON THE SWEAT TEST IN ADULT PATIENTS WITH CYSTIC-FIBROSIS
    ROBERTS, CM
    BUTLAND, RJA
    SAUNDERS, C
    GREENLAND, JH
    HODSON, ME
    RESPIRATORY MEDICINE, 1989, 83 (06) : 479 - 480
  • [35] Age-dependent alteration of the serum-unbound fraction of nicardipine, a calcium-channel blocker, in man
    Sugioka, N
    Koyama, H
    Kawakubo, M
    Ohta, T
    Kishimoto, H
    Mori, S
    Nakajima, K
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1996, 48 (12) : 1327 - 1331
  • [36] NON-INVASIVE MEASUREMENT OF THE ACUTE HEMODYNAMIC-EFFECTS OF A NEW CALCIUM-CHANNEL BLOCKER, NICARDIPINE
    CAMPBELL, B
    KELMAN, A
    SUMNER, D
    GILBERT, L
    GRAHAM, D
    HILLIS, S
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 17 (02) : P188 - P189
  • [37] Lipid emulsion treatment of cardiotoxicity caused by calcium channel blocker and beta-blocker
    Sohn, Ju-Tae
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2022, 58 : 331 - 332
  • [38] EFFECTS OF A CALCIUM-CHANNEL BLOCKER, NICARDIPINE, ON PRESSURE-NATRIURESIS IN DAHL SALT-SENSITIVE RATS
    TAKENAKA, T
    SUZUKI, H
    IKENAGA, H
    ITAYA, Y
    YAMAKAWA, H
    SAKAMAKI, Y
    SARUTA, T
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 1994, 16 (01) : 77 - 88
  • [39] FLUNARIZINE, A CALCIUM-CHANNEL BLOCKER, IN THE PROPHYLACTIC TREATMENT OF MIGRAINE
    DIAMOND, S
    SCHENBAUM, H
    HEADACHE, 1983, 23 (01): : 39 - 42
  • [40] UNPREDICTABLE PHARMACOKINETICS AND TARGETING TREATMENT OF CALCIUM CHANNEL BLOCKER OVERDOSE
    Hanson, Elizabeth
    Kakkera, Krishna
    CRITICAL CARE MEDICINE, 2024, 52